New thrombopoietic growth factors

Blood

Volumn 109, Issue 11, 2007, Pages 4607-4616

  Kuter, David J ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Hematology Division   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AKR 501; AMG 531; ELTROMBOPAG; FC RECEPTOR; GROWTH FACTOR; INTERFERON; JANUS KINASE 2; PLACEBO; PROMACTA; RECOMBINANT MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; RECOMBINANT THROMBOPOIETIN; STAT PROTEIN; THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR; UNCLASSIFIED DRUG;

BLEEDING; CLINICAL TRIAL; DOSE RESPONSE; DRUG BINDING; DRUG HALF LIFE; DRUG MECHANISM; HEADACHE; HEPATITIS C; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LEUKEMIA; LIVER DISEASE; MYELOFIBROSIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOCYTOSIS; THROMBOSIS; TUMOR GROWTH;

EID: 34249733156     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-10-019315     Document Type: Review

References (84)

1. Bartley TD, Bogenberger J, Hunt P, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell. 1994;77:1117-1124.
2. Lok S, Kaushansky K, Holly RD, et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature. 1994;369:565-568.
3. Kuter DJ, Beeler DL, Rosenberg RD. The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci U S A. 1994;91:11104-11108.
4. Kato T, Ogami K, Shimada Y, et al. Purification and characterization of thrombopoietin. J Biochem. 1995;118:229-236.
5. de Sauvage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature. 1994;369:533-538.
6. Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood. 2002;100:3457-3469.
7. Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001;98:3241-3248.
8. Basser RL, O'Flaherty E, Green M, et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood. 2002;99:2599-2602.
9. Kuter DJ. Thrombopoietin. In: Oppenheim JJ, Feldmann M, Durum SK, Hirano T, Vilcek J, Nicola NA, eds. Cytokine Reference: A Compendium of Cytokines and Other Mediators of Host Defense. New York, NY: Academic Press; 2000:965-982.
10. Feese MD, Tamada T, Kato Y, et al. Structure of the receptor-binding domain of human thrombopoietin determined by complexation with a neutralizing antibody fragment. Proc Natl Acad Sci U S A. 2004;101:1816-1821.
11. Kuter DJ, Li JL. Thrombopoietin receptor. In: Oppenheim JJ, Feldmann M, Durum SK, Hirano T, Vilcek J, Nicola NA, eds. Cytokine Reference: A Compendium of Cytokines and Other Mediators of Host Defense. New York, NY: Academic Press; 2000:1953-1968.
12. Alexander WS, Metcalf D, Dunn AR. Point mutations within a dimer interface homology domain of c-Mpl induce constitutive receptor activity and tumorigenicity. EMBO J. 1995;14:5569-5578.
13. Sabath DF, Kaushansky K, Broudy VC. Deletion of the extracellular membrane-distal cytokine receptor homology module of Mpl results in constitutive cell growth and loss of thrombopoietin binding. Blood. 1999;94:365-367.
14. Remy I, Wilson IA, Michnick SW. Erythropoietin receptor activation by a ligand-induced conformation change. Science. 1999;283:990-993.
15. Livnah O, Stura EA, Middleton SA, Johnson DL, Jolliffe LK, Wilson IA. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science. 1999;283:987-990.
16. Stoffel R, Wiestner A, Skoda RC. Thrombopoietin in thrombocytopenic mice: evidence against regulation at the mRNA level and for a direct regulatory role of platelets. Blood. 1996;87:567-573.
17. Siemensma NP, Bathal PS, Penington DG. The effect of massive liver resection on platelet kinetics in the rat. J Lab Clin Med. 1975;86:817-833.
18. Quin S, Fu F, Li W, Chen Q, de Sauvage FJ. Primary role of the liver in thrombopoietin production shown by tissue-specific knockout. Blood. 1998;92:2189-2191.
19. Peck-Radosavljevic M, Zacherl J, Meng YG, et al. Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver? J Hepatol. 1997;27:127-131.
20. Peck-Radosavljevic M, Wichlas M, Zacherl J, et al. Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production. Blood. 2000;95:795-801.
21. Li J, Xia Y, Kuter D. Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacodynamics. Br J Haematol. 1999;106:345-356.
22. Broudy VC, Lin NL, Sabath DF, Papayannopoulou T, Kaushansky K. Human platelets display high-affinity receptors for thrombopoietin. Blood. 1997;89:1896-1904.
23. Li J, Xia Y, Kuter DJ. Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics. Br J Haematol. 1999;106:345-356.
24. Gurney AL, Wong SC, Henzel WJ, de Sauvage FJ. Distinct regions of c-Mpl cytoplasmic domain are coupled to the JAK-STAT signal transduction pathway and Shc phosphorylation. Proc Natl Acad Sci U S A. 1995;92:5292-5296.
25. Fielder PJ, Gurney AL, Stefanich E, et al. Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood. 1996;87:2154-2161.
26. Fielder PJ, Hass P, Nagel M, et al. Human platelets as a model for the binding and degradation of thrombopoietin. Blood. 1997;89:2782-2788.
27. Kuter DJ, Rosenberg RD. Appearance of a megakaryocyte growth-promoting activity, megapoietin, during acute thrombocytopenia in the rabbit. Blood. 1994;84:1464-1472.
28. Giri JG, Smith WG, Kahn LE, et al. Promegapoietin, a chimeric growth factor for megakaryocyte and platelet restoration [abstract]. Blood. 1997;90:580a.
29. Vadhan-Raj S, Murray LJ, Bueso-Ramos C, et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Int Med. 1997;126:673-681.
30. Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med. 2000;132:364-368.
31. Begley CG, Basser RL. Biologic and structural differences of thrombopoietic growth factors. Semin Hematol. 2000;37:19-27.
32. Kuter DJ, Goodnough LT, Romo J, et al. Thrombopoietin therapy increases platelet yields in healthy platelet donors. Blood. 2001;98:1339-1345.
33. Schuster MW, Beveridge R, Frei-Lahr D, et al. The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation. Exp Hematol. 2002;30:1044-1050.
34. Bolwell B, Vredenburgh J, Overmoyer B, et al. Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation. Bone Marrow Transplant. 2000;26:141-145.
35. Nash RA, Kurzrock R, DiPersio J, et al. A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2000;6:25-34.
36. Somlo G, Sniecinski I, ter Veer A, et al. Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy. Blood. 1999;93:2798-2806.
37. Fibbe WE, Heemskerk DP, Laterveer L, et al. Accelerated reconstitution of platelets and erythrocytes after syngeneic transplantation of bone marrow cells derived from thrombopoietin pre-treated donor mice. Blood. 1995;86:3308-3313.
38. Schiffer CA, Miller K, Larson RA, et al. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood. 2000;95:2530-2535.
39. Archimbaud E, Ottmann OG, Yin JA, et al. A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood. 1999;94:3694-3701.
40. Douglas VK, Tallman MS, Cripe LD, Peterson LC. Thrombopoietin administered during induction chemotherapy to patients with acute myeloid leukemia induces transient morphologic changes that may resemble chronic myeloproliferative disorders. Am J Clin Pathol. 2002;117:844-850.
41. Fanucchi M, Glaspy J, Crawford J, et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med. 1997;336:404-409.
42. Basser RL, Rasko JE, Clarke K, et al. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood. 1997;89:3118-3128.
43. Basser RL, Underhill C, Davis I, et al. Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer. J Clin Oncol. 2000;18:2852-2861.
44. Vadhan-Raj S, Patel S, Broxmeyer H, et al. Schedule-dependent reduction in thrombocytopenia by recombinant human thrombopoietin (rhTPO) in patients with sarcoma receiving high dose chemotherapy (CT) with adriamycin (A) and ifosfamide (I) [abstract]. J Clin Oncol. 1999;18:52A.
45. Nomura S, Dan K, Hotta T, Fujimura K, Ikeda Y. Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood. 2002;100:728-730.
46. Rice L, Nichol JL, McMillan R, Roskos LK, Bacile M. Cyclic immune thrombocytopenia responsive to thrombopoietic growth factor therapy. Am J Hematol. 2001;68:210-214.
47. Goodnough LT, Kuter DJ, McCullough J, et al. Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin. Blood. 2001;98:1346-1351.
48. Vadhan-Raj S, Kavanagh JJ, Freedman RS, et al. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study. Lancet. 2002;359:2145-2152.
49. Cwirla SE, Balasubramanian P, Duffin DJ, et al. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science. 1997;276:1696-1699.
50. de Serres M, Ellis B, Dillberger JE, et al. Immunogenicity of thrombopoietin mimetic peptide GW395058 in BALB/c mice and New Zealand white rabbits: evaluation of the potential for thrombopoietin neutralizing antibody production in man. Stem Cells. 1999;17:203-209.
51. Frederickson S, Renshaw MW, Lin B, et al. A rationally designed agonist antibody fragment that functionally mimics thrombopoietin. Proc Natl Acad Sci U S A. 2006;103:14307-14312.
52. Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther. 2004;76:628-638.
53. Bussel J, Kuter DJ, George JN, et al. Effect of a thrombopoiesis- stimulating protein (AMG-531) in chronic immune thrombocytopenic purpura. N Engl J Med. 2006;355:1-14.
54. Broudy VC, Lin NL. AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine. 2004;25:52-60.
55. Cerneus D, Brown K, Harris R, et al. Stimulation of platelet production in healthy volunteers by a novel pegylated peptide-based thrombopoietin (TPO) receptor agonist. Blood. 2005;106:abstract 1249.
56. Duffy KJ, Darcy MG, Delorme E, et al. Hydrazinonaphthalene and azonaphthalene thrombopoietin mimics are nonpeptidyl promoters of megakaryocytopoiesis. J Med Chem. 2001;44:3730-3745.
57. Duffy KJ, Shaw AN, Delorme E, et al. Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules, 1: discovery and optimization of salicylaldehyde thiosemicarbazone thrombopoietin mimics. J Med Chem. 2002;45:3573-3575.
58. Duffy KJ, Price AT, Delorme E, et al. Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules, 2: Rational design of naphtho[1,2-d]imidazole thrombopoietin mimics. J Med Chem. 2002;45:3576-3578.
59. Erickson-Miller CL, DeLorme E, Tian SS, et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol. 2005;33:85-93.
60. Luengo JI, Duffy KJ, Shaw AN, et al. Discovery of SB-497115, a small-molecule thrombopoietin (TPO) receptor agonist for the treatment of thrombocytopenia. Blood. 2004;104:795a
61. Erickson-Miller C, Delorme E, Iskander M, Giampa L, Hopson CB, Luengo JI, Duffy KJ, Dillon SB, Rosen J, Miller S, Lamb P, Tian SS. Species specificity and receptor domain interaction of a small molecule TPO receptor agonist. Blood. 2004;104:abstract 2909.
62. Desjardins RE, Tempel DL, Lucek R, Kuter DJ. Single and multiple oral doses of AKR-501 (TM477) increase the platelet count in healthy volunteers. Blood. 2006;108:abstract 477.
63. Suzuki K, Abe M, Fukushima-Shintani M, et al. YM477, a novel orally-active thrombopoietin receptor agonist. Blood. 2005;106:abstract 2298.
64. Erickson-Miller CL, Delorme E, Tian SS, et al. Discovery and characterization of a selective, non-peptidyl thrombopoietin receptor agonist [abstract]. Blood. 2000;96:675a.
65. Erickson-Miller C, Delorme E, Giampa L, et al. Biological activity and selectivity for Tpo receptor of the orally bioavailable, small molecule Tpo receptor agonist, SB-497115. Blood. 2004;104:abstract 2912.
66. Safonov IG, Heerding DA, Keenan RM, et al. New benzimidazoles as thrombopoietin receptor agonists. Bioorg Med Chem Lett. 2006;16:1212-1216.
67. Kalota A, Brennan K, Erickson-Miller C, Danet G, Carroll M, Gewirtz A. Effects of SB559457, a novel small molecule thrombopoietin receptor agonist, on heamtopoietic cell growth and differentiation. Blood. 2004;104:abstract 2913.
68. Jenkins J, Nicholl R, Williams D, et al. An oral, non-peptide, small molecule thrombopoietin receptor agonist increases platelet counts in healthy subjects. Blood. 2004;104:abstract 2916.
69. Orita T, Tsunoda H, Yabuta N, et al. A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor. Blood. 2005;105:562-566.
70. Kai M, Motoki K, Yoshida H, et al. Domain subclass conversion improved activity of anti-Mpl agonist antibodies in the form of whole IgG. Blood. 2006;108:abstract 1134.
71. Kuter DJ, Bussel J, George JN, et al. Long-term dosing of AMG 531 in thrombocytopenic patients with immune thrombocytopenic purpura: 48 week update. Blood. 2006;108:abstract 476.
72. Bussel J, Cheng G, Saleh M, Kovaleva L, Stone N, Mayer B, Jenkins J, Provan A. Analysis of bleeding in patients with immune thrombocytopenic purpura (ITP): a randomized, double-blind, placebo-controlled trial of eltrombopag, an oral platelet growth factor. Blood. 2006;108:abstract 475.
73. McHutchinson JG, Afdhal NH, Dusheiko G, et al. Eltrombopag, an oral platelet growth factor, facilitates initiation of interferon therapy in subjects with HCV associated thrombocytopenia: results from a phase II placebo controlled, double-blind, dose-ranging study [abstract]. Hepatology. 2006;44:692a.
74. Harker LA. Platelets in thrombotic disorders: quantitative and qualitative platelet disorders predisposing to arterial thrombosis. Semin Hematol. 1998;35:241-252.
75. Harker LA, Marzec UM, Hunt P, et al. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. Blood. 1996;88:511-521.
76. Harker LA, Hunt P, Marzec UM, et al. Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates. Blood. 1996;87:1833-1844.
77. Peng J, Friese P, Wolf RF, et al. Relative reactivity of platelets from thrombopoietin- and interleukin-6-treated dogs. Blood. 1996;87:4158-4163.
78. Columbyova L, Loda M, Scadden DT. Thrombopoietin receptor expression in human cancer cell lines and primary tissues. Cancer Res. 1995;55:3509-3512.
79. Ulich TR, del Castillo J, Senaldi G, et al. Systemic hematologic effects of PEG-rHuMGDF-induced megakaryocyte hyperplasia in mice. Blood. 1996;87:5006-5015.
80. Yan XQ, Lacey D, Fletcher F, et al. Chronic exposure to retroviral vector encoded MGDF (mplligand) induces lineage-specific growth and differentiation of megakaryocytes in mice. Blood. 1995;86:4025-4033.
81. Yan XQ, Lacey D, Hill D, et al. A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): reversal of disease by bone marrow transplantation. Blood. 1996;88:402-409.
82. Frey BM, Rafii S, Teterson M, Eaton D, Crystal RG, Moore MA. Adenovector-mediated expression of human thrombopoietin cDNA in immune-compromised mice: insights into the pathophysiology of osteomyelofibrosis. J Immunol. 1998;160:691-699.
83. Villeval JL, Cohen-Solal K, Tulliez M, et al. High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood. 1997;90:4369-4383.
84. Yanagida M, Ide Y, Imai A, et al. The role of transforming growth factor-beta in PEG-rHuMGDF-induced reversible myelofibrosis in rats. Br J Haematol. 1997;99:739-745.